COMMUNIQUÉS West-GlobeNewswire

Ocular Therapeutix™ Announces Board of Directors and Leadership Updates
22/02/2024
Industry Leader and Retina Expert, Pravin U. Dugel, MD, Becomes Executive Chair Jeffrey S. Heier, MD to become Chief Scientific Officer, Peter K. Kaiser, MD to be Medical Director, and Sanjay Nayak, MBBS, PhD to become [...]
Bitech Technologies Appoints Sid Sung as Its New Chief Innovation Officer to Lead the Digital Revolution in the Renewable Energy Industry
22/02/2024
Newport Beach, CA, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Bitech Technologies Corporation [ OTCQB: BTTC ], (“the Company” or “Bitech”) a global technology solution provider dedicated to green energy solutions, is delighted [...]
BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
22/02/2024
- Submitted New Drug Application (NDA) to US Food and Drug Administration (FDA) for acoramidis for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) based on positive results of Phase 3 ATTRibute-CM trial [...]
Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024
22/02/2024
WEST CHESTER, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring [...]
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress
22/02/2024
On track to dose the first patient in the Phase 3 MAGNITUDE trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy in Q1 2024 Expect to initiate the Phase 3 study of NTLA-2002 for [...]
InflaRx Appoints Jan Medina as Head of Investor Relations
22/02/2024
JENA, Germany, Feb. 22, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced the appointment of [...]
The Joint Corp. to Host Conference Call on Thursday, March 7th to Discuss Fourth Quarter and Year-end 2023 Results
22/02/2024
SCOTTSDALE, Ariz., Feb. 22, 2024 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), the nation's largest provider of chiropractic care through The Joint Chiropractic ® network, announced it will report its fourth [...]
Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan
22/02/2024
-- Supplemental cohort of 12 Japanese patients to be added to global Phase 3 hypothalamic obesity trial, with dosing expected to begin in third quarter of 2024 -- -- Significant unmet need with 5,000 to 8,000 patients [...]
Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update
22/02/2024
-- Fourth quarter 2023 net revenue from global sales of IMCIVREE ® (setmelanotide) of $24.2 million -- -- Enrollment completed in 120-patient, pivotal cohort of Phase 3 setmelanotide trial in hypothalamic obesity; top- [...]
Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
22/02/2024
KT-474/SAR444656 (IRAK4) Phase 2 program advancing in HS and AD with data expected in first half of 2025 KT-621 (STAT6) expected to start Phase 1 in second half of 2024 and KT-294 (TYK2) expected to start Phase 1 in [...]
Chimerix to Report Fourth Quarter and Year End 2023 Financial Results and Provide an Operational Update on February 29, 2024
22/02/2024
DURHAM, N.C., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases [...]
SpringWorks Therapeutics to Present at Upcoming Investor Conferences
22/02/2024
STAMFORD, Conn., Feb. 22, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that management [...]
ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference
22/02/2024
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Feb. 22, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of therapeutics targeting toxic [...]
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates
22/02/2024
BURLINGTON, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system [...]
Agios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024
22/02/2024
CAMBRIDGE, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that the company is [...]
C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
22/02/2024
CFT1946 Preclinical Data Accepted for a Poster Presentation at the AACR Annual Meeting 2024 Phase 1 Dose Escalation Trials for CFT7455 and CFT1946 Continue to Progress; Data from Both Trials Expected in 2H 2024 Well [...]
Solei Brand Launches New Cannabis Infused Cold Brew Teas
22/02/2024
REFRESHING ELEVATION IN EVERY SIP: Peach Cranberry and Wildberry Hibiscus Infused Cold Brew Teas are Now Available in Canada TORONTO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") ( [...]
Sharecare to report fourth quarter and full year fiscal 2023 financial results on Wednesday, March 13
22/02/2024
ATLANTA, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Sharecare (Nasdaq: SHCR ), the digital health company that helps people manage all their health in one place, today announced that it will report fourth quarter and full year [...]
Ventyx Biosciences to Present Results of the Phase 2 Trial of VTX002 in Ulcerative Colitis at the 19th Congress of the European Crohn's and Colitis Organisation (ECCO)
22/02/2024
Results of the Phase 2 trial of VTX002 (S1P1R modulator) in ulcerative colitis to be highlighted in oral presentation on February 22 nd SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX [...]

Pages